A Medical Case Study with Sarepta Therapeutics CEO Doug Ingram

Sarepta has come under scrutiny over Elevidys, its gene therapy for Duchenne Muscular Dystrophy (DMD). With a one-time treatment cost of $3.2 million, many families have struggled to secure insurance approval. The company has also faced heightened concern following the deaths of several patients on the drug. But for many in the DMD community, Elevidys still represents the best hope in the face of the fatal disease. Sarepta’s CEO Doug Ingram discusses the controversy head-on.